rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Marc Rubin

Director

Company insider

Files Form 4 as: Director, Curis; Director, Galectin Therapeutics; Executive Chairman, Titan Pharmaceuticals; Director, Medarex.

Every Form 4 they filed

In numbers

Trades disclosed
106
Buys
15
Sells
5
Bought
$457K
Sold
$759K
Companies
4
Companies where not an officer
3
First trade
30 Nov 2007
Last trade
7 Jul 2026
Last filed
9 Jul 2026

Companies traded

Where they are an officer
Titan PharmaceuticalsDirector, Officer, 10% owner · last 5 Jan 20229 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
CRIS CurisDirector · Biotechnology · last 7 Jul 20262 buys · 1 sell
GALT Galectin TherapeuticsDirector · Biotechnology · last 23 Jan 20254 buys · 4 sells
MedarexDirector · last 1 Sep 20090 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
7 Jul 2026filed 9 Jul 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A$36K6,800 at $5.29filing
7 Jul 2026filed 9 Jul 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A$36K6,800 at $5.29filing
20 Mar 2026filed 23 Mar 2026CRIS CurisBiotechnologySEC FORM 4 Code C—26,667filing
20 Mar 2026filed 23 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code C—20filing
20 Mar 2026filed 23 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code C—20filing
20 Mar 2026filed 23 Mar 2026CRIS CurisBiotechnologySEC FORM 4 Code C—26,667filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—20filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—26,667filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—26,667filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—20filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—26,667filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—26,667filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—26,667filing
17 Mar 2026filed 18 Mar 2026CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A—26,667filing
20 May 2025filed 22 May 2025CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A$45K14,400 at $3.13filing
28 Jan 2025filed 30 Jan 2025CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A$5,0081,600 at $3.13filing
23 Jan 2025filed 27 Jan 2025GALT Galectin Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—60,000 at $0.00filing
21 May 2024filed 23 May 2024CRIS Curisoption or derivative · BiotechnologySEC FORM 4 Code A$49K4,250 at $11.62filing
24 Jan 2024filed 7 Feb 2024GALT Galectin Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
26 Jan 2023filed 30 Jan 2023GALT Galectin Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing

News

Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)CRIS · themarketsdaily.com · 17 Oct 2026

0 headlines in the last 90 days name Marc Rubin; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care11
Not placed9

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.